Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer-Reference-Cited by-同舟云学术

Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer

Published:2012-04 Issue:5 Volume:13 Page:615-624
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Hamada Akinobu¹²,Sasaki Ji-ichiro³,Saeki Sho²,Iwamoto Norihiro⁴,Inaba Megumi⁵,Ushijima Sunao⁵,Urata Maki⁶,Kishi Hiroto⁶,Fujii Shinji⁷,Semba Hiroshi⁷,Kashiwabara Kosuke⁸,Tsubata Yukari⁹,Kai Yuki²,Isobe Takeshi⁹,Kohrogi Hirotsugu²,Saito Hideyuki³²

Affiliation:

1. Kumamoto University Hospital, Kumamoto, Japan.

2. Kumamoto University, Kumamoto, Japan

3. Kumamoto University Hospital, Kumamoto, Japan

4. Saiseikai Kumamoto Hospital, Kumamoto, Japan

5. Kumamoto Central Hospital, Kumamoto, Japan

6. Kumamoto City Hospital, Kumamoto, Japan

7. Kumamoto Regional Medical Center, Kumamoto, Japan

8. Kumamoto Medical Center, Kumamoto, Japan

9. Shimane University Hospital, Shimane, Japan

Abstract

Aims: We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with non-small-cell lung cancer. Materials & methods: After erlotinib 150 mg was administered to 50 patients, ABCB1 polymorphisms were analyzed via either TaqMan® assays or direct nucleotide sequencing. Plasma concentrations were measured by HPLC. Results: The trough concentration at steady state in patients with the ABCB1 1236TT–2677TT–3435TT genotype was higher compared with others groups (p = 0.021) and patients carrying this genotype had a higher risk of developing higher grade 2 toxicity (p = 0.012). Conclusion: The present study suggested that the ABCB1 1236TT–2677TT–3435TT genotype was associated with higher plasma concentration and the risk of developing higher toxicity in patients treated with erlotinib. Original submitted 5 August 2011; Revision submitted 30 November 2011

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.11.176

Reference48 articles.

1. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

2. EGFRMutation and Response of Lung Cancer to Gefitinib

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

5. Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer;Drug Resistance Updates;2022-05

2. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers;Molecular Cancer;2022-02-24

3. Rhabdomyolysis Caused by Gefitinib Overdose: A Case Report;Internal Medicine;2022

4. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101);The Oncologist;2020-08-11

5. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer;JAMA Oncology;2020-07-09